Progress, Pitfalls, and Impact of AI-Driven Clinical Trials.

Journal: Clinical pharmacology and therapeutics
PMID: 39722473

Abstract

Since the deep learning revolution of the early 2010s, significant efforts and billions of dollars have been invested in applying artificial intelligence (AI) to drug discovery and development (AIDD). However, despite high expectations, few AI-discovered or AI-designed drugs have entered human clinical trials, and none have achieved clinical approval. In this perspective, we examine the challenges impeding progress and highlight opportunities to harness AI's potential in transforming drug discovery and development.

Authors

  • Dominika Wilczok
    Duke University, Durham, North Carolina, USA.
  • Alex Zhavoronkov
    Pharmaceutical Artificial Intelligence Department, Insilico Medicine, Inc., Emerging Technology Centers, Johns Hopkins University at Eastern, Baltimore, Maryland, USA.

Keywords

External Resources

Popular Topics
Recent Journals